Enlivex Therapeutics Ltd. Quarterly Liabilities in USD from Q4 2017 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
Enlivex Therapeutics Ltd. quarterly Liabilities history and growth rate from Q4 2017 to Q2 2025.
  • Enlivex Therapeutics Ltd. Liabilities for the quarter ending June 30, 2025 was $3.54M, a 6.11% increase year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2025 $3.54M +$204K +6.11% Jun 30, 2025 6-K 2025-08-29
Q4 2024 $4.1M -$2.65M -39.3% Dec 31, 2024 6-K 2025-08-29
Q2 2024 $3.34M -$5.35M -61.6% Jun 30, 2024 6-K 2024-08-30
Q4 2023 $6.75M -$4.05M -37.5% Dec 31, 2023 20-F 2025-04-30
Q2 2023 $8.69M -$162K -1.83% Jun 30, 2023 6-K 2023-09-01
Q4 2022 $10.8M +$694K +6.87% Dec 31, 2022 20-F 2024-04-30
Q2 2022 $8.86M +$3.87M +77.8% Jun 30, 2022 6-K 2022-08-22
Q4 2021 $10.1M +$5.24M +107% Dec 31, 2021 20-F 2023-04-10
Q2 2021 $4.98M -$264K -5.03% Jun 30, 2021 6-K 2021-08-06
Q4 2020 $4.87M -$1.41M -22.4% Dec 31, 2020 20-F 2022-04-29
Q2 2020 $5.25M Jun 30, 2020 6-K/A 2020-10-13
Q4 2019 $6.28M +$4.95M +373% Dec 31, 2019 20-F 2021-04-30
Q4 2018 $1.33M +$281K +26.8% Dec 31, 2018 20-F 2020-04-30
Q4 2017 $1.05M Dec 31, 2017 20-F 2019-04-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.